Sunny Pharmtech Inc. (TPEX:6676)
Taiwan
· Delayed Price · Currency is TWD 15.75
-0.05 (-0.32%)
Mar 10, 2026, 1:56 PM CST
Sunny Pharmtech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 290.18 | 418.01 | 428.83 | 359.59 | 241 | 419.94 | Upgrade
|
| Revenue Growth (YoY) | -40.17% | -2.52% | 19.26% | 49.21% | -42.61% | 79.09% | Upgrade
|
| Cost of Revenue | 134.7 | 191.61 | 143.3 | 152.88 | 125.25 | 195.87 | Upgrade
|
| Gross Profit | 155.48 | 226.4 | 285.53 | 206.71 | 115.75 | 224.07 | Upgrade
|
| Selling, General & Admin | 178.35 | 170.11 | 148.76 | 138.45 | 120.39 | 116.37 | Upgrade
|
| Research & Development | 231.14 | 219.28 | 208.87 | 255.88 | 171.37 | 182.04 | Upgrade
|
| Operating Expenses | 409.49 | 389.39 | 357.62 | 394.33 | 291.75 | 298.41 | Upgrade
|
| Operating Income | -254.01 | -162.99 | -72.1 | -187.62 | -176 | -74.34 | Upgrade
|
| Interest Expense | -9.74 | -9.07 | -11.24 | -4.59 | -5.62 | -6.8 | Upgrade
|
| Interest & Investment Income | 3.37 | 4.54 | 5.73 | 1.38 | 0.36 | 1.48 | Upgrade
|
| Currency Exchange Gain (Loss) | -9.56 | 10.74 | 12.23 | 16.15 | -3.18 | -26.69 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.42 | 0.7 | 3.38 | 4.53 | 3.31 | 2.88 | Upgrade
|
| EBT Excluding Unusual Items | -269.51 | -156.08 | -62 | -170.15 | -181.14 | -103.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.08 | -0.08 | -0.09 | - | - | Upgrade
|
| Asset Writedown | - | - | -1.24 | - | - | -6.18 | Upgrade
|
| Other Unusual Items | - | - | - | - | 4.48 | 7.89 | Upgrade
|
| Pretax Income | -269.51 | -156 | -63.32 | -170.24 | -174.79 | -101.76 | Upgrade
|
| Earnings From Continuing Operations | -269.51 | -156 | -63.32 | -170.24 | -174.79 | -101.76 | Upgrade
|
| Net Income | -269.51 | -156 | -63.32 | -170.24 | -174.79 | -101.76 | Upgrade
|
| Net Income to Common | -269.51 | -156 | -63.32 | -170.24 | -174.79 | -101.76 | Upgrade
|
| Shares Outstanding (Basic) | 149 | 149 | 143 | 139 | 134 | 129 | Upgrade
|
| Shares Outstanding (Diluted) | 149 | 149 | 143 | 139 | 134 | 129 | Upgrade
|
| Shares Change (YoY) | 0.66% | 4.20% | 3.04% | 3.60% | 3.29% | 2.70% | Upgrade
|
| EPS (Basic) | -1.81 | -1.05 | -0.44 | -1.23 | -1.31 | -0.79 | Upgrade
|
| EPS (Diluted) | -1.82 | -1.05 | -0.44 | -1.23 | -1.31 | -0.79 | Upgrade
|
| Free Cash Flow | -145.81 | -82.81 | -105.88 | -152.3 | -193.31 | -91.04 | Upgrade
|
| Free Cash Flow Per Share | -0.98 | -0.56 | -0.74 | -1.10 | -1.45 | -0.70 | Upgrade
|
| Gross Margin | 53.58% | 54.16% | 66.58% | 57.48% | 48.03% | 53.36% | Upgrade
|
| Operating Margin | -87.53% | -38.99% | -16.81% | -52.18% | -73.03% | -17.70% | Upgrade
|
| Profit Margin | -92.88% | -37.32% | -14.77% | -47.34% | -72.53% | -24.23% | Upgrade
|
| Free Cash Flow Margin | -50.25% | -19.81% | -24.69% | -42.35% | -80.21% | -21.68% | Upgrade
|
| EBITDA | -137.79 | -48.45 | 41.34 | -83.09 | -76.24 | 26.9 | Upgrade
|
| EBITDA Margin | -47.48% | -11.59% | 9.64% | -23.11% | -31.64% | 6.40% | Upgrade
|
| D&A For EBITDA | 116.22 | 114.54 | 113.44 | 104.53 | 99.76 | 101.24 | Upgrade
|
| EBIT | -254.01 | -162.99 | -72.1 | -187.62 | -176 | -74.34 | Upgrade
|
| EBIT Margin | -87.53% | -38.99% | -16.81% | -52.18% | -73.03% | -17.70% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.